Drug Trial Radar · NCT06770582
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Jun 3, 2025
Primary completion
Feb 1, 2032
Study completion Feb 1, 2032
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving pembrolizumab with radiation may kill more tumor cells than chemotherapy with radiation therapy in patients with non-muscle invasive bladder cancer.
Conditions
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
- Stage I Bladder Cancer AJCC v8
Interventions
Biospecimen CollectionProcedure
Undergo blood and urine sample collection
CisplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT
FluorouracilDrug
Given IV
GemcitabineDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
MitomycinDrug
Given IV
PembrolizumabBiological
Given IV
Questionnaire AdministrationOther
Ancillary studies
Radiation TherapyRadiation
Undergo radiation therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bladder intact event-free survival (BIEFS)Time frame: Up to 5 years
- Global quality of lifeTime frame: Up to 5 years
Locations
147 sites in 2 countries. Site status is shown where the registry gives one.
Banner University Medical Center - Tucson
Tucson, Arizona · Active not recruiting
Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas · Recruiting
Highlands Oncology Group - Rogers
Rogers, Arkansas · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
Los Angeles General Medical Center
Los Angeles, California · Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Shaw Cancer Center
Edwards, Colorado · Recruiting
Helen F Graham Cancer Center
Newark, Delaware · Recruiting
Medical Oncology Hematology Consultants PA
Newark, Delaware · Recruiting
Mount Sinai Comprehensive Cancer Center at Aventura
Aventura, Florida · Recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Recruiting
Mount Sinai Medical Center
Miami Beach, Florida · Recruiting
Grady Health System
Atlanta, Georgia · Recruiting
Emory Proton Therapy Center
Atlanta, Georgia · Recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Recruiting
Emory Saint Joseph's Hospital
Atlanta, Georgia · Recruiting
Rush MD Anderson Cancer Center
Chicago, Illinois · Recruiting
Carle at The Riverfront
Danville, Illinois · Recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois · Recruiting
Decatur Memorial Hospital
Decatur, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Recruiting
Crossroads Cancer Center
Effingham, Illinois · Recruiting
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois · Recruiting
Carle BroMenn Medical Center
Normal, Illinois · Recruiting
Carle Cancer Institute Normal
Normal, Illinois · Recruiting
HSHS Saint Elizabeth's Hospital
O'Fallon, Illinois · Recruiting
Southern Illinois University School of Medicine
Springfield, Illinois · Recruiting
Springfield Clinic
Springfield, Illinois · Recruiting
Springfield Memorial Hospital
Springfield, Illinois · Recruiting
Carle Cancer Center
Urbana, Illinois · Recruiting
Mary Greeley Medical Center
Ames, Iowa · Recruiting
McFarland Clinic - Ames
Ames, Iowa · Recruiting
UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa · Recruiting
Mercy Cancer Center-West Lakes
Clive, Iowa · Recruiting
UI Health Care Mission Cancer and Blood - West Des Moines Clinic
Clive, Iowa · Recruiting
Iowa Methodist Medical Center
Des Moines, Iowa · Recruiting
Showing 40 of 147 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.